Options for treatment of primary biliary cirrhosis

Drugs

Volumn 64, Issue 20, 2004, Pages 2261-2271

  Oo, Ye H ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AUTOANTIBODY; AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; COLCHICINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; LAMIVUDINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PRANLUKAST; RIFAMPICIN; SULINDAC; THALIDOMIDE; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ANTIBODY TITER; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CHOLESTASIS; CHRONIC DISEASE; CLINICAL TRIAL; COLON ADENOMA; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GRANULOMATOSIS; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; LETHARGY; LIVER TRANSPLANTATION; OSTEOPOROSIS; PALLIATIVE THERAPY; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RECTUM ADENOMA; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SURVIVAL; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; ANTIPRURITICS; CHOLAGOGUES AND CHOLERETICS; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PRURITUS; URSODEOXYCHOLIC ACID;

EID: 6344277442     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464200-00001     Document Type: Review

References (69)

1. Laurin JM, Lindor KD. Primary biliary cirrhosis. Dig Dis 1994 Nov-Dec; 12 (6): 331-50
2. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis 2003 Nov; 7 (4): 779-94
3. Newton JL, Jones DE, Metcalf JV, et al. Presentation and mortality of primary biliary cirrhosis in older patients. Age Ageing 2000; 29: 305-9
4. Heathcote EJ. Management of primary biliary cirrhosis: the American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31 (4): 1005-13
5. James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999; 30 (2): 390-4
6. Verma A, Jazrawi RP, Ahmed HA, et al. Prescribing habits in primary biliary cirrhosis: a national survey. Eur J Gastroenterol Hepatol 1999; 11 (8): 817-20
7. Paumgartner G, Beuers U. UDCA in cholestatic liver disease: mechanism of action and therapeutic use revisited. Hepatology 2002; 36: 525-31
8. Jazrawi RP, de Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106(1): 134-42
9. Setchell KD, Rodrigues CM, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997; 112 (1): 226-35
10. Guldutuna S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104 (6): 1736-44
11. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of UDCA therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354 (9184): 1053-60
12. Neuberger J. URSO: panacea or placebo? Hepatology 2000; 31 (4): 1027-8
13. Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999 Mar; 29 (3): 644-7
14. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; (1): CD 000551
15. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19(5): 1149-56
16. Lindor KD, Janes CH, Crippin JS, et al. Bone disease in primary biliary cirrhosis: does Ursodeoxycholic acid make a difference? Hepatology 1995; 21 (2): 389-92
17. Huet PM, Huet J, Deslauriers J. Portal hypertension in patients with primary biliary cirrhosis. In: Lindor KD, Heathcote EJ, Poupon R, editors. Primary biliary cirrhosis: from pathogenesis to treatment. London: Kluwer Academic Publishers, 1998: 87-91
18. van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, et al. Single or multiple dose Ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol 1996; 25 (6): 887-94
19. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72 (12): 1137-40
20. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of Ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113 (3): 884-90
21. Roda E, Azzaroli F, Nigro G, et al. Improved liver tests and greater biliary enrichment with high dose UDCA in early stage primary biliary cirrhosis. Dig Liver Dis 2002; 34 (7): 523-7
22. Pasha T, Heathcote J, Gabriel S, et al. Cost-effectiveness of Ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999; 29 (1): 21-6
23. Yamazaki K, Suzuki K, Nakamura A, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with PBC. Hepatology 1999; 30: 71-8
24. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003; 38(1): 203-9
25. Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in nrsodiol-treated patients. Gastroenterology 2002; 122 (3): 652-8
26. Lanzini A, De Tavonatti MG, Panarotto B, et al. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during Ursodeoxycholic acid administration. Gut 2003; 52 (9): 1371-5
27. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985; 89 (5): 1084-91
28. Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104 (2): 519-26
29. Jones EA, ten Kate FJW, ter Borg F, et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 1165-9
30. Bonis PA, Kaplan M. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology 1999; 117 (2): 395-9
31. Kaplan MM, Schmid C, Provenzale D, et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999; 117 (5): 1173-80
32. Hendrickse MT, Rigney E, Giaffer MH, et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117 (2): 400-7
33. Bach N, Bodian C, Bodenheimer H, et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (1): 187-93
34. Combes B, Emerson S, Flye NL. Primary biliary cirrhosis (PBC) Ursodiol (UDCA) plus Methotrexate or its Placebo study (PUMPS) [abstract]. Hepatology 2003; 38: 112
35. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117 (4): 918-25
36. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31 (2): 318-23
37. Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38 (1): 196-202
38. Almasio PL, Floreani A, Chiaramonte M, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther 2000; 14 (12): 1645-52
39. Lee YM, Kaplan MM. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. Am J Gastroenterol 2003; 98 (1): 205-8
40. Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991; 14 (6): 990-3
41. Devlin J, O'Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut 1999; 45 Suppl. 6: VI1-VI22
42. Neuberger J, Farrant M. Chapter 5. In: Williams R, Portmann B, Tan KC, editors. The practice of liver transplantation. Edinburgh: Churchill Livingstone, 1995
43. Poison RJ, Portmann B, Neuberger J, et al. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis: clinical and histologic follow-up studies. Gastroenterology 1989; 97 (3): 715-25
44. Balan V, Batts KP, Porayko MK, et al. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993; 18 (6): 1392-8
45. Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33 (1): 22-7
46. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20 (2): 137-40
47. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10(1): 1-7
48. Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation in patients with primary biliary cirrhosis: use of prognostic modeling. J Hepatol 1999; 30 (2): 285-92
49. Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998; 28(1): 33-8
50. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23 (5): 1148-53
51. UNOS. MELD/PELD calculator [online]. Available from URL: http://www.unos.org/resources/MeldPeldCalculator.asp [Accessed 2004 Jun 28]
52. MacQuillan GC, Neuberger JM. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003; 7 (4): 941-56
53. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in post-menopausal women. N Engl J Med 1993; 328: 460-4
54. Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118(1): 145-51
55. Guanabens N, Pares A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (10): 2268-74
56. Menon KV, Angulo P, Boe GM, et al. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 889-92
57. Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38 (6): 573-8
58. Miyaguchi S, Oda M, Saito H, et al. Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy. Hepatogastroenterology 1998; 45 (23): 1457-61
59. Leuschner M, Holtmeier J, Ackermann H, et al. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol 2002; 14 (12): 1369-76
60. Tan AC, Mulder CJ. Increased survival in advanced primary biliary cirrhosis patients with regular albumin infusions? Eur J Gastroenterol Hepatol 1999; 11 (8): 927-30
61. Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis. Proc Natl Acad Sci U S A 2003; 100: 8454-9
62. Mason A, Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr Gastroenterol Rep 2002; 4: 45-51
63. Reddy A, Prince M, James OF, et al. Tamoxifen: a novel treatment for primary biliary cirrhosis? Liver Int 2004 Jun; 24 (3): 194-7
64. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268-74
65. Poupon RE, Baikau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis: UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548-54
66. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90
67. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-90
68. Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515-8
69. Poupon RE, Lindor KD, Pare's A, et al. Combined analysis of the effects of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-6